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1. Introduction
For past several decades, laboratory animal models have been the prevailing paradigm for
studying human diseases. A classic approach is to study the impact of specific genes
through the use of gain- or loss-of-function mutant animals. While the animal models have
greatly contributed to our understanding of the etiology and mechanisms of disease, they
often fall short of fully recapitulating human pathophysiology and translating to clinical ap‐
plications due to interspecies physiologic differences. In a review of preclinical studies of
animal models published in high-impact scientific journals, approximately one-third trans‐
lated to the level of human randomized trials and only one-tenth were subsequently ap‐
proved clinically for patient use [1]. This attrition rate would have been even higher if less
frequently cited animal research had been included. These unresolved issues with animal
models have set the stage for the emergence of human embryonic stem cell (hESC) and hu‐
man induced pluripotent stem cell (hiPSC) for modeling human diseases.
Laid out in this chapter, we will discuss the development of various stem cell paradigms includ‐
ing mESC, hESC, and hiPSC (Figure 1); examine the utilization of these models via studies of
cardiac diseases; assess the current limitations and future challenges; and finally conclude with
the prospective outlook and viability of the field holistically in the scope of disease modeling.
2. Human cardiovascular diseases
According to the American Heart Association, cardiovascular diseases (CVD) remains the
leading cause of deaths in United States, accounting for 32.8% of all deaths or roughly one of
every three deaths [2]. To put into perspective, that is an average of 1 death every 39 sec‐
© 2013 Sheng and Hong; licensee InTech. This is an open access article distributed under the terms of the
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onds. CVD is a generic term that encompasses conditions that affect the circulatory system,
including myocardial infarction, angina pectoris, heart failure, stroke, and congenital cardio‐
vascular defects. Both genetic and environmental factors are implicated in the pathogenesis
of CVDs. While some risk factors such as lifestyle habits and family history have been iden‐
tified for CVDs, much more remains to be learned about the pathophysiology, optimal man‐
agement, and proper prevention. Moreover, genetic predispositions like abnormalities in
specific ion channels and sarcomere proteins pose special diagnostic and therapeutic chal‐
lenges. In fact, for most heritable forms of heart diseases, current treatment options leave
much to be desired.
Figure 1. Timeline of stem cell modeling progress. Stem cell platforms are a new technology that was only intro‐
duced within the last two decades. The most recent breakthrough in hiPSC occurred just six years ago.
3. Stem cell disease modeling
Despite much progress in the past couple decades in the discovery of the molecular and ge‐
netic causes of many heart diseases, a detailed mechanic understanding of failing heart at
the cellular level remains rudimentary. The main reason for this situation is the lack of ac‐
cess to live human tissues and unproven human cardiomyocyte cell culture models. Post‐
partum, cardiomyocytes become terminally differentiated and cease to proliferate, thus
making isolation and culture of human myocardial cells extremely challenging. One surro‐
gate for human cardiomyocyte culture is the use of rat neonatal cardiomyocytes, which has
been shown to yield 8.4x106 cells per heart [3]. However, with both human and rat neonatal
cardiomyocytes, the inability to continuously passage cells and scarcity of resource make
them unsustainable candidates for disease modeling.
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Figure 2. Overview of the stem cell disease modeling process. The blue and yellow lightning bolts indicate the
addition of reprogramming and directed differentiation factors, respectively.
Furthermore, special considerations must be taken into account for critical differences be‐
tween animal and human cardiomyocytes, in terms of cell biological, mechanical and elec‐
trophysiological properties. The lack of appropriate human heart disease models have
hindered development of rational therapies, and the prospects for new therapies to treat
heart diseases remain dim despite tremendous advances in various animal models. An alter‐
native human biology based approach for heart disease modeling is to use human stem cells
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as a renewable source of cells for cardiomyocytes. In the following section, we will discuss
the various stem cell platforms (mESC, hESC, & hiPSC) for disease modeling, with specific
focus on cardiovascular diseases (Figure 2).
3.1. mESC paradigm
In 1981, the first pluripotent mouse embryonic stem cells (mESCs) were isolated in vitro by
culturing the inner cell mass of pre-implantation mouse blastocysts [4, 5]. These cells were
capable of self-renewal and pluripotent differentiation into all three germ layers (ectoderm,
mesoderm, and endoderm) [6]. The initial studies demonstrated a proof of concept, showing
the feasibility of isolating pluripotent cells directly from early embryos. The unique capabili‐
ty of culturing pluripotent cells in vitro provided the means for genetic manipulation via se‐
lection or transformation of specific DNA fragments, and importantly to develop genetic
mouse models of human disease. This platform allowed researchers to begin exploring path‐
ways in cardiac development to dissect underlying molecular and cellular mechanisms
causing congenital defects and other abnormalities.
While the general use of mESCs was promising, inherent problems with using animal mod‐
els remained in the context of studying disease pathogenesis and pathophysiology. One of
the crucial points of divergence is the shear difference in size and complexity between hu‐
mans and mice both macroscopically and genomically [7]. Consequently, disease suscepti‐
bility may vary drastically. For instance, a mouse heart is ten thousand times smaller but
beats roughly seven times faster than that of a human. The two organisms also differ in their
expression of myosin heavy chain (MHC) isoforms. βMHC is the predominant isoform in
fetal mouse hearts, whereas mainly αMHC is expressed in adults; conversely, the vice versa
is true for humans [8]. Furthermore, mice are resistant to the development of coronary athe‐
rosclerosis even on a high-fat, high-cholesterol diet, because they lack cholesteryl ester trans‐
fer protein (CETP), an enzyme responsible for the transfer of cholesterol from high-density
lipoprotein to low-density lipoprotein [9].
3.2. hESC paradigm
Building on the initial discovery of mESC technologies, increased research focus has been
directed towards developing a human-based stem cell approach in anticipation of creating a
more accurate disease model. It would be another seventeen years before human embryonic
stem cells (hESCs) derived from the inner cell mass of the human blastocyst (stage 4-5 days
post-fertilization) were isolated by Thomson et al. in 1998 [10]. Many factors hindered the
transition from mESC to hESC, such as the limited availability of surplus human embryos,
stringent growth requirements for culturing hESC, and the shroud of ethical controversies.
Generating hESCs require the destruction of the donor embryo that is considered a potential
human life by some ethical and religious groups. The debate revolving around hESC has de‐
terred many researchers, mainly in the United States, from pursuit of this technology. In Au‐
gust of 2001, President Bush became the first President to provide federal funding for
embryonic stem cell research, albeit limited to experimenting with only the 15 existing stem
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cell lines [11]. Nonetheless, this discovery paved the way for modeling diseases directly on a
human-based paradigm.
In a study in 2009, Lu et al. evaluated long-term safety and function of retinal pigment epitheli‐
um (RPE) as preclinical models of macular degeneration using hESCs [10]. When hESC-in‐
duced RPE were subsequently transplanted into mutant mice, they demonstrated long-term
functional rescue, though progressively deteriorating function was noted due to the immuno‐
genic response elicited by the xenografts. The initial data showed promise for future elucidation
of macular degenerative disease pathophysiology. However, there were important obstacles to
widespread clinical translation. First, transplantation of hESC requires immunosuppression,
since the cells are allogeneic. In addition, a well known risk of this technology is the formation of
teratomas, tumor-like formations containing tissues belonging to all three germ layers, if some
undifferentiated pluripotent cells are transplanted [12]. Finally, perhaps the biggest obstacle to
a widespread acceptance of human ESC transplantation is ethical and religious, as derivation of
human ESCs typically involves the consumption of a human embryo.
3.3. hiPSC paradigm
Given these obstacles to a widespread use of the human ESCs, a new stem cell technology, hu‐
man induced pluripotent stem cells (hiPSCs), has rapidly overtaken hESC research. Introduced
in 2006 by Takahashi and Yamanaka, hiPSCs have been hailed as “the molecular equivalent of
the discovery of antibiotics or vaccines in the last century [13].” The technology revolutionized
the stem cell field, and for his achievement, Yamanaka received the 2012 Nobel Prize in Medi‐
cine.” In a span of just six years, the field has rapidly expanded the repertoire of reprogramma‐
ble terminally differentiated tissue into hiPSC (keratinocytes [14, 15], hepatocytes [16], adipose-
derived stem cells [17, 18], neural stem cells [19], astrocytes [20], cord blood [21, 22], amniotic
cells [23], peripheral blood [24, 25], mesenchymal stromal cells [26], oral mucosa fibroblasts [27],
and T-cells [28]). Most recently, the ability to generate hiPSC from Epstein-Barr virus (EBV)-im‐
mortalized B cell lines (lymphoblastoid B-cell lines) provides the opportunity to obtain samples
from disease cohort repositories such as the Coriell Institute for Medical Research or the UK Bio‐
bank [29, 30].
In parallel, tremendous progress has been made towards the directing differentiation of
these hiPSCs into various cell fates (neural progenitors [31], [32] motor neurons [33] [34],
dopaminergic neurons [35], retinal cells [36], hepatocytes [37], blood cells [25, 38], adipo‐
cytes [39], endothelial cells [37, 38], fibroblasts [40, 41], and cardiomyocytes [42]). In theory,
these patient-derived hiPSCs should be capable of differentiating into all of the >210 adult
cell lineages. Nonetheless, our current growing repertoire sets the stage for studying various
disease mechanisms in the laboratory, with the caveat that monogenic diseases such as long-
QT syndrome will be much easier to model than complex diseases like Parkinson’s.
As alluded to above, the somatic cell reprogramming offers several distinct advantages over
embryonic stem cells. In the U.S. particularly, funding may be scarce at times due to the
government’s political stance regarding stem cell research. Importantly, somatic cells can be
obtained from individual patients, enabling the development of truly personalized diagnos‐
tics and therapeutics.
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4. Modeling cardiovascular diseases
While there is a wide array of cardiovascular diseases, we chose to focus on several with well-
defined clinical presentation, strong genetic component, and significant research progress
(Long QT syndrome types 1 and 2, Timothy syndrome, LEOPARD syndrome, & dilated cardio‐
myopathy; see Table 1). As discussed below, the paradigm of using stem cells to model inherit‐
ed  cardiovascular  diseases  is  rapidly  being  established  and  validated.  Moreover,  these
advances with the rare inherited conditions may lead to new paradigms to study the much more
prevalent acquired heart and vascular diseases at the cellular and molecular levels.
Genetic Disorder Mutation Main findings
Long QT syndrome
Type 1




marked prolonged action potentials; dominant negative trafficking defect
associated with a 70 to 80% reduction in Iks current; altered channel activation
and deactivation properties; increased susceptibility to catecholamine-induced
tachyarrhythmia attenuated by β-blockage
Long QT syndrome
Type 2
Lahti et al. (2012) [83] KCNH2R176W
prolonged action potential; reduced Ikr density; more sensitive to potentially
arrhythmogenic drugs; more pronounced inverse correlation between the
beating rate and repolarization time




significant reduction of potassium current IKr; marked arrhythmogenecity;
evaluated potency of existing & novel pharmacological agents
Matsa et al. (2011) [84] KCNH2G1681A
prolonged field/action potential duration; Ikr blocker & isoprenaline induced
arrhythmias presenting as early after depolarizations; attenuated by β-blockers
propranolol & nadolol
Timothy syndrome




irregular contraction; excess Ca2+ influx; prolonged action potentials; irregular
electrical activity; abnormal calcium transients in ventricular-like cells; roscovitine







hypertrophic cardiomyopathy; higher degree of sarcomeric organization;
preferential localization of NFATC4 in the nucleus
Dilated
cardiomyopathy
Sun et al. (2012) [67] TNNT2R173W
altered regulation of Ca2+; decreased contractility; abnormal distribution of
sarcomeric α-actinin; β-drenergic agonist induced cellular stress; β-adrenergic
blockers or overexpression of Serca2a improved function
Table 1. hiPSC studies modeling cardiovascular diseases.
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4.1. Long QT syndrome
Long-QT syndrome (LQTS) is a rare congenital channelopathy disease that is characterized
by an abnormally prolonged ventricular repolarization phase, inherited primarily in an au‐
tosomal dominant manner but sometimes autosomal recessively. It was first described in
1957 in a family with normal parents and two healthy children but also in which three chil‐
dren experienced recurrent syncope and sudden death [43]. Electrocardiography (EKG)
studies showed prolonged QT interval due to increased ventricular action potential, hence
the name of the disease (Figure 3). The prevalence of LQTS in the U.S. is approximately 1 in
7,000 individuals, causing 2,000 to 3,000 sudden deaths annually in children or adolescents
[44]. This abnormality can lead to an increased risk of such reported incidence of sudden
death, usually triggered by the resulting ventricular fibrillation or torsade de pointes (poly‐
morphic ventricular tachycardia). Depending on the specific gene mutation, long-QT syn‐
drome can be classified into 12 genetic subtypes [45]. Together, LQT1, LQT2, and LQT3
genotypes account for 97% of the mutations identified to date [46].













b) Surface EKG 







Figure 3. Long QT Syndrome. a) a visual representation of the cardiac action potential during depolarization and
repolarization of the cell. There are 4 phases of the cycle in which various ion channels open and close, causing the
flux of charged ions (red: into the cell & blue: out of the cell) and reflecting the change in overall action potential. b)
an illustration of a normal surface EKG plot, highlighting the QT interval in particular. In long QT syndrome, a clear
indication is the prolongation of that interval on an EKG.
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Our  current  understanding  of  how  mutations  in  ion  channels  cause  disease  can  only
be  extrapolated  from,  at  best,  mammalian  cell  lines  such  as  immortalized  human  em‐
bryonic  kidney  293  cells  or  Xenopus  oocytes  using  heterologous  expression  systems de‐
signed  with  the  mutant  channel  of  interest  [47].  Commonly  used  mouse  models  are
not  apt  for  studying  LQTS  because  the  IKr  current  is  essentially  absent  in  the  mouse
heart.  With  the  advent  of  patient-derived  iPSC  technology,  cardiac  induction  of  these
cell  lines  may  recapitulate  their  respective  disease  pathophysiology  in  vitro,  providing
a  unique  platform  for  studying  cellular  and  molecular  mechanisms  and  assessing  the
efficacy of  various therapies.
4.1.1. Long QT syndrome type 1
The most common type LQT1, accounting for roughly 45% of genotyped patients, results
from mutations of the alpha subunit of the slow delayed rectifier potassium channel
KvLQT1, encoded by gene KCNQ1 on chromosome 11 [48]. In a recent study aimed at reca‐
pitulating disease phenotype using patient-derived iPSCs, Moretti et al. initially screened a
family affected by LQTS type 1 through genotyping and electrophysiology studies, identify‐
ing an autosomal dominant missense mutation R190Q of KCNQ1 [48]. Then, they reprog‐
rammed skin fibroblast from two affected family members into iPSCs and directed cardiac
induction to yield spontaneously beating cardiomyocytes. Finally, they characterized these
heart cells through whole-cell patch clamp, observing reduced Iks, a slow delayed rectifier
potassium current, by 70-80%, altered Iks activation and deactivation properties, and an ab‐
normal response to catecholamine stimulation.
Not only were Moretti et al. able to capture characteristics of LQTS type 1 in vitro, they were
also able to demonstrate physiologically how beta-blockers, clinically administered as a pro‐
phylactic therapy for asymptomatic LQTS type 1 patients, had protective effects against cat‐
echolamine-induced tachyarrhythmia by reducing early afterdepolarizations [49]. This
ability to mimic LQTS type 1 in an in vitro human model paved way for similar studies in‐
volving other genetic diseases.
4.1.2. Long QT syndrome type 2
Similar to LQTS type 1, LQTS type 2 is another mutation arising from the alpha subunit of a
potassium channel, but one with different properties: a KCNH2 (also known as hERG)-en‐
coded rapid delayed rectifier potassium channel [50]. A diagnostic finding in patients is the
onset of clinical symptoms such as syncope triggered by sudden loud noises [45].
In a study by Itzhaki et al., A614V missense mutation was identified in the KCNH2 gene in a
28 year old patient with clinically diagnosed type 2 LQTS [50]. Dermal fibroblast samples
were obtained, reprogrammed to generate patient-specific human iPSCs, and through retro‐
viral transduction, differentiated into embryoid bodies of spontaneously beating cardiomyo‐
cytes. Through the use of these iPSC-generated heart cells, they were able to conduct
electrophysiology studies and test the effects of pharmacological intervention. Itzhaki et al.
found marked prolonged action potential duration and significantly reduced peak ampli‐
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tudes of IKr activation and tail currents in the cells derived from the LQTS patient compared
to those generated from a healthy individual, both hallmark signatures of LQTS. They also
reported observing early-after depolarizations in 66% of the iPSC-CMs on both cellular and
multicellular levels, a key finding suggestive of arrhythmogenicity that explains sudden
death in LQTS patients clinically. With the amount of clinical evidence extracted from these
patient-derived cardiomocytes, this novel technology can serve as an excellent in vitro dis‐
ease model for understanding cellular & molecular pathogenesis and becomes a very viable
option for personalized medicine in the future.
4.2. Timothy syndrome
In contrast to the previously detailed potassium channel defects that lead to LQTS, Timothy
syndrome is a form of LQTS caused by a missense mutation in the L-type calcium channel
Cav1.2, encoded by the CACNA1C gene. This is the predominant L-type channel in the
mammalian heart, which is essential for normal heart development and excitation-contrac‐
tion coupling [51]. Mutations in this Ca2+ channel cause delayed channel closing and conse‐
quently, increased cellular excitability.
Concurrent  with  Itzhaki  et  al.’s  publication  LQTS  type  2,  Yazawa  et  al.  reported  their
findings on Timothy syndrome using a patient-derived iPSC-CM disease model [52].  To
summarize,  using  a  similar  cardiac  induction  protocol,  they  successfully  reproduced  in
vitro cardiomyocytes exhibiting clinical Timothy syndrome phenotypes. Electrophysiology
and calcium imaging studies showed irregular contraction, excess Ca2+  influx, prolonged
action potentials,  irregular electrical activity, and abnormal calcium transients in ventric‐
ular-like cells.
One of the key findings in their study was the functional difference between Timothy syn‐
drome and LQTS type 1 cardiomyocytes. Unlike the latter where both ventricular- and at‐
rial-like cells had prolonged action potentials, only ventricular Timothy syndrome
cardiomyocytes exhibited this phenotype. Additionally, drug-induced triggering of arrhyth‐
mias and delayed depolarizations in LQTS type 1 cells were not necessary, because they
were observed spontaneously in Timothy syndrome cells. While a direct correlation has yet
to be established to the clinical outcomes (i.e. torsades de points and ventricular fibrillation),
this study is another proof-of-concept that iPSC-CMs are invaluable for examining detailed
pathogenesis of human diseases.
4.3. LEOPARD syndrome
LEOPARD syndrome is an autosomal-dominant developmental disorder with clinical mani‐
festations described by its acronym: lentigines, electrocardiographic abnormalities, ocular
hypertelorism, pulmonary valve stenosis, abnormal genitalia, retardation of growth, and
deafness [53]. It is caused by a mutation in the PTPN11 gene, which impairs the catalytic re‐
gion of the encoded SHP2 phosphatase [54]. Currently, drosophila [55] and zebrafish [56]
models of LEOPARD syndrome have been described in literature, but the molecular basis of
pathogenesis remains to be addressed.
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In 2010, Carvajal-Vergara et al.  successfully demonstrated the use of iPSC technology to
characterize  LEOPARD syndrome in  vitro  [57].  One of  the clinical  hallmarks of  the dis‐
ease  is  hypertrophic  cardiomyopathy.  In  this  study,  iPSC-CMs  derived  from  a  25-year
old  female  patient  with  the  condition  were  compared  to  those  differentiated  a  healthy
brother  as  a  control.  Carvajal-Vergara  et  al.  showed,  by  comparison  to  the  wild-type,
larger  patient-derived  iPSC-CMs  with  a  higher  degree  of  sarcomeric  organization  and
preferential  localization of  NFATC4 (calcineurin-NFAT pathway is  an important  regula‐
tor  of  cardiac hypertrophy [58])  in the nucleus [57].  Using antibody microarrays on pa‐
tient-specific iPSCs, they also noted increased phosphorylation of certain proteins such as
MEK1 leading to perturbations in the RAS-MAPK signaling cascade, which can begin to
provide  some  preliminary  understanding  and  elucidation  of  LEOPARD  syndrome’s
pathogenesis on a molecular level [57].
4.4. Dilated cardiomyopathy
As previously mentioned, cardiovascular disease is the leading cause of morbidity and mor‐
tality worldwide, projected to represent 30% of all deaths in 2015 [59]. In the United States
alone, heart disease accounts for roughly one-third of all deaths [60]. Of those, dilated cardi‐
omyopathy (DCM) is one of the leading causes of heart failure and is associated with sub‐
stantial mortality [61]. It leads to progressive cardiac remodeling, characterized by
ventricular dilatation, hypertrophy, and systolic dysfunction [62]. In an estimated 20% to
48% of cases depending on the study, DCM is identified as a familial disorder with strong
heritability [63]. Mutations in over 30 genes have been shown to be disease causing or dis‐
ease associated [64].
One of the more common genetic defects causing DCM is a mutation in the cardiac troponin
T gene (TNNT2) [65]. Mouse models have already provided invaluable insight to the disease
mechanism. For instance, mice still displayed normal phenotype after knockout of one
TNNT2 allele, because they only lead to a mild deficit in transcript but not protein [66]. Fur‐
thermore, the severity of DCM depends on the ratio of mutant to wild-type TNNT2 tran‐
script, since mutant protein is associated with cardiomyocyte Ca2+ desensitization [66].
However, given the differences in electrophysiological and developmental properties, in vi‐
tro human models of DCM would conceivably provide a more precise platform for under‐
standing molecular basis of pathogenesis.
In Sun et al.’s study published in 2012, they characterized iPSC-CMs from a family carry‐
ing a point  mutation (R173W) in the TNNT2 gene by comparing to healthy individuals
in the same cohort [67].  These patient-specific cardiomyocytes from diseased individuals
exhibited dysregulated calcium handling, decreased contractility, and abnormal heteroge‐
nous distribution of sarcomeric α-actinin. The overexpression of Serca2a, a gene therapy
treatment for heart failure currently in clinical trials [68], significantly improved the con‐
tractility  force  generated  by  iPSC-CMs derived  from DCM patients  [67].  Much like  the
use  of  hiPSC  technology  for  other  cardiovascular  diseases  discussed  previously,  it  ap‐
pears to be a robust system for describing pathogenesis of disease that has yielded pre‐
liminary positive results.
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5. Stem cell disease modeling challenges
In the framework of disease modeling, both hESC and hiPSC technologies still have unre‐
solved issues to address. For instance, hESCs display chromosomal instability with long-
term in vitro culture [69], and iPSCs undergo dynamic changes in copy number variations
during reprogramming, especially in the early passages [70]. In the U.S., research funding
for hESC often fluctuates, subjecting to restrictions imposed by Congress and its current
stance on the destruction of fertilized human embryos. The advantage of hiPSC over hESC is
that it bypasses this controversy and generates autologous cells while maintaining key char‐
acteristics: morphology, feeder dependency, surface markers, gene expression, promoter
methylation status, telomerase activities, in vitro differentiation potential, and in vivo terato‐
ma forming capacity [71]. These features heavily favor hiPSC technology as the predomi‐
nant approach for disease modeling over hESCs.
In the near future, the hiPSC model faces several main challenges. One of the concerns is
developing a robust and efficient methodology for yielding large quantities of differenti‐
ated  and  functional  cells  of  a  designated  lineage.  Depending  on  the  protocol  and  cell
lines  used,  efficiencies  can  range  anywhere  from  <0.0001%  to  >50%.  Specifically  in  the
case  of  cardiac  induction,  the  hiPSC-induced  cardiomyocytes  resemble  immature  fetal
cardiomyocytes in their gene expression profile (key marker is β-tubulin) as well as elec‐
trophysiologic  and  structural  properties  [72].  Resolving  this  hindrance  will  also  have
great  impact  on facilitating in  vivo  studies  and widespread applications in drug discov‐
ery and development.
The practicality of  studying disease pathogenesis in vitro,  especially those with systemic
involvement,  raises  another  question.  This  intrinsic  lack  of  an  in  vivo  environment  pre‐
vents a global understanding of how a disease may impact the body and simplifies inter‐
actions of  basic signaling pathways.  For more complex diseases,  it  may also be difficult
to replicate conditions in a petri dish with a single lineage cell type, even if done via co-
cultures.  Furthermore,  the  current  designation  of  a  control  line  is  arbitrary  since  it  is
mainly a criterion of exclusions. In diseases such as Alzheimer’s or Parkinson’s,  there is
a long latency period, which would be hard to mimic in vitro due to the dynamics of re‐
al-time  disease  progression.  Studies  are  currently  underway  to  assess  the  possibility  of
accelerating disease progression in  vitro  via  exposure to  environmental  factors  contribu‐
ting to the disease such as oxidative stress [73].
Finally, not all diseases can be readily modeled using hiPSCs. For example, patients with
Fanconi anemia have a defective DNA repair mechanism, and therefore cannot be reprog‐
rammed without antecedent gene correction [74]. For other conditions, some may exhibit
low penetrance or do not follow a simple Mendelian form of inheritance and are affected by
a multitude of factors ranging from the environment to epigenetics. The latter in diseased
state may become an inevitable confounding factor working with iPSCs, because of its con‐
tribution to the low efficiency of reprogramming and its stochastic nature. In a study by
Meissner et al., sub-clone lineages transfected with an Oct4-GFP reporter were obtained
from early appearing iPSC colonies and displayed temporally different expression patterns
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of GFP, some never expressing it at all [75]. Because of the sensitivity to epigenetic events,
the use of histone deacetylase (HDAC) inhibitors may help promote self-renewal and/or di‐
rected differentiation of stem cells [76].
6. Future outlook & research direction
The intent of stem cell technology was to recapitulate, as closely as possible, disease pheno‐
type in the human body for three primary outcomes: disease modeling, drug discovery &
development, and regenerative medicine. The first of which will provide the initial platform
from which drugs and therapeutic applications can be derived. In some cases, a treatment
could be discovered before the underlying disease mechanism is understood, because pa‐
tient-derived hiPSCs can be differentiated without any genetic modifications in vitro into the
desired cell type and characterized in drug screenings.
In the context of patient-derived cardiomyocytes, while not a perfect in vivo surrogate, they
will still be one of the better models currently available due to their identical genomes and
phenotype. The complex interactions of normal human physiology is incredibly difficult to
mimic outside the host, let alone recapitulating a diseased phenotype. The mouse model is
currently the most common mammalian system used to study human physiology for several
reasons: 90% genetic homology with comparable genomic sizes, relatively easy mainte‐
nance, rapid cost-effective breeding under laboratory settings, and capability for genetic ma‐
nipulation. It is great for initial studies and insight into basic understanding and elucidation
of the mechanisms underlying the disease.
Building on the gradual advancement from mESC to hESC to the current hiPSC technology,
one of the technical goals remains to be removing all extrinsic factors with the goal of mim‐
icking in vivo conditions. Most established mESC and hESC protocols relied on a fibroblast
feeder-cell layer for culture and proliferation, which secrete undefined substrates into the
medium and cause batch-to-batch variation [77]. Similarly, initial hiPSC protocols used a
mouse embryonic fibroblast (MEF) feeder-cell layer that had similar problems [78]. In 2011,
Yu et al. developed a feeder-free system with chemically defined medium and also replaced
conventional transfection of somatic cells with footprint-less episomal reprogramming using
small molecules to generate hiPSCs [79].
Furthermore, mESC and hESC-directed differentiation formed embryoid bodies (EBs),
which are spheroids with an inner layer of ectoderm and a single outer layer of endoderm.
These EBs differentiate to derivatives of all 3 primary germ layers, leaving a very low yield
of spontaneously contracting cardiomyocytes. While this was sufficient for initial studies,
larger quantities of pure cardiomyocytes are necessary to establish a scalable system for dis‐
ease modeling and drug development. In 2007, Laflamme et al. reported the use of a mono‐
layer cardiac induction system based on activin A and BMP4 with a 30-fold higher yield of
pure cardiomyocytes than through the formation of EBs [80]. Most recently, Lian et al. of the
Wisconsin stem cell group identified temporal modulation of canonical Wnt signaling as a
key step for robust cardiomyocyte differentiation reporting efficient yields of up to 98% [81].
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Further studies are needed to evaluate the optimal cardiac induction protocol. Once a ro‐
bust, universal, and scalable system for directed differentiation of iPSCs into cardiomyo‐
cytes is established, we can provide an inexhaustible supply of patient-derived cells for
research and therapeutic purposes.
6.1. Zinc finger nucleases
With some host-specific  modifications,  currently  available  technologies  such as  zinc  fin‐
ger  nucleases  can  be  applied  as  the  next  step  in  disease  modeling  after  understanding
the pathogenesis,  developing a cure.  Zinc finger nucleases are enzymes that  manipulate
specific sites of the host genome, generating transgenic lines via knocking-in and knock‐
ing-out  of  genes.  The  homologous  recombination  pathway,  naturally  occurring at  DNA
replication  forks  and  repairing  double  stranded  breaks,  can  be  exploited  to  selectively
target a locus for modification while leaving the rest of the genome in tact [82]. Through
this  method,  we have been able  to  identify  new gene function in  mouse and other  ho‐
mologous mammalian models. The same concept can be applied to gene therapy for hu‐
mans.  For  example,  with  patient-specific  cardiomyocytes,  constructs  can be  created and
tested in vitro to restore wild-type function.
6.2. High-throughput screening
High-throughput screening is another means of advancing disease therapy, but it hinges
on its scalability; in other words, whether or not cells of the disease model can be mass-
produced. With current protocols for directed cardiac differentiation, every round of ex‐
periments  would  take  at  least  2  weeks  [81].  If  hiPSC-derived  cardiomyocytes  could  be
consistently  generated  in  96-well  plates,  then  these  high-throughput  screenings  that
could propel translational research from a cellular and molecular level of disease directly
to therapeutic applications.
7. Conclusion
In the new era of personalized medicine, the stem cell platform for disease modeling ap‐
pears very viable, especially given the rapid advancements in the field over the past several
decades. We have thoroughly discussed the advantages and disadvantages of using mESC,
hESC, and hiPSC, all of which have the common end goal of best recapitulating disease phe‐
notype in vitro. Of those, we strongly believe that hiPSC-derived cells can eventually be the
gold standard for personalized medicine. Using a heritable cardiovascular class of diseases
as an example, we endeavored to convey the potential benefits of harnessing iPSC technolo‐
gy to study the pathogenesis of various disorders. One of the most difficult challenges cur‐
rently is establishing a robust, universal, and scalable cardiac induction protocol. Combined
with the genetic tools available, we will be able to break the barriers to disease modeling
with the limitless supply of human cells in vitro.
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